Illumina (ILMN) Stock Forecast & Price Target

$94.66 -8.05 (-7.84%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$94.20 -0.45 (-0.48%)

As of 08/1/2025 07:57 PM Eastern

Illumina - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 20 Analyst Ratings

Sell
2

Hold
9

Buy
9

Based on 20 Wall Street analysts who have issued ratings for Illumina in the last 12 months, the stock has a consensus rating of "Hold." Out of the 20 analysts, 2 have given a sell rating, 9 have given a hold rating, 8 have given a buy rating, and 1 has given a strong buy rating for ILMN.

Consensus Price Target

$127.21
34.39% Upside

According to the 20 analysts' twelve-month price targets for Illumina, the average price target is $127.21. The highest price target for ILMN is $200.00, while the lowest price target for ILMN is $80.00. The average price target represents a forecasted upside of 34.39% from the current price of $94.66.

Get the Latest News and Ratings for ILMN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Illumina and its competitors.

ILMN Analyst Ratings Over Time

Type	Current Forecast 8/2/24 to 8/2/25	1 Month Ago 7/3/24 to 7/3/25	3 Months Ago 5/4/24 to 5/4/25	1 Year Ago 8/3/23 to 8/2/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	9 Buy rating(s)	9 Buy rating(s)
Hold	9 Hold rating(s)	9 Hold rating(s)	10 Hold rating(s)	10 Hold rating(s)
Sell	2 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$127.21	$127.39	$137.55	$158.57
Forecasted Upside	34.39% Upside	26.83% Upside	76.62% Upside	34.73% Upside
Consensus Rating	Hold	Hold	Hold	Hold

ILMN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ILMN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Illumina Stock vs. The Competition

Type	Illumina	Medical Companies	S&P 500
Consensus Rating Score	2.40	2.81	2.53
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	34.39% Upside	10,285.41% Upside	14.62% Upside
News Sentiment Rating	Positive News See Recent ILMN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/1/2025	Royal Bank Of Canada 4 of 5 stars	Conor McNamara Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$118.00 ➝ $126.00	+30.04%
8/1/2025	Canaccord Genuity Group 2 of 5 stars	Kyle Mikson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Hold ➝ Hold	$99.00 ➝ $105.00	+9.19%
8/1/2025	Barclays 3 of 5 stars	Luke Sergott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Underweight ➝ Underweight	$85.00 ➝ $90.00	-7.83%
7/28/2025	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Catherine Ramsey Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$84.00 ➝ $105.00	-3.93%
7/11/2025	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Sung Ji Nam Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$125.00	+24.94%
7/9/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Patrick Donnelly Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell	$85.00 ➝ $80.00	-19.41%
7/8/2025	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Vijay Kumar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$116.00 ➝ $128.00	+31.76%
5/20/2025	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mason Carrico Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$105.00 ➝ $105.00	+26.58%
5/15/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Westenberg Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$190.00 ➝ $185.00	+129.39%
5/12/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Tejas Savant Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$136.00 ➝ $100.00	+24.99%
Get the Latest News and Ratings for ILMN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.
5/9/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Julia Qin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$120.00 ➝ $85.00	+12.20%
5/9/2025	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Subbu Nambi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$122.00 ➝ $114.00	+48.17%
2/28/2025	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Gupta Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
2/28/2025	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$100.00	+12.40%
2/7/2025	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brennan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$177.00 ➝ $140.00	+14.01%
11/5/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$133.00 ➝ $145.00	-4.89%
10/17/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$160.00 ➝ $200.00	+38.91%
8/28/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Hellweg Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$150.00	+14.59%
8/16/2024	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Nakagiri Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/16/2024	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$120.00 ➝ $154.00	+19.57%
6/3/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$115.00	+10.28%
3/20/2024	OTR Global Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Positive ➝ Mixed
12/15/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Market Perform
12/13/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$175.00	+48.76%
12/12/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underperform	$140.00 ➝ $100.00	-14.99%
10/12/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$200.00	+49.91%
8/10/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$225.00 ➝ $200.00	+8.41%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 04:17 AM ET.

Should I Buy Illumina Stock? ILMN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, August 1, 2025. Please send any questions or comments about these Illumina pros and cons to contact@marketbeat.com.

Illumina
Bull Case

Here are some ways that investors could benefit from investing in Illumina, Inc.:

The current stock price is around $106, which may present a buying opportunity for investors looking for value in the life sciences sector.
Illumina, Inc. has recently reported earnings that exceeded consensus estimates, indicating strong financial performance and potential for growth.
Institutional investors hold a significant portion of the stock, with 89.42% owned by such entities, suggesting confidence in the company's future prospects.
The company has a positive return on equity, which reflects its ability to generate profit from shareholders' equity, a favorable sign for potential investors.
Illumina, Inc. is a leader in genetic and genomic analysis solutions, which positions it well in a growing market driven by advancements in healthcare and personalized medicine.

Illumina
Bear Case

Investors should be bearish about investing in Illumina, Inc. for these reasons:

The company has a negative net margin, indicating that it is currently spending more than it earns, which could be a concern for profitability.
Illumina's stock has experienced volatility, with a 12-month high of $156.66 and a low of $68.70, suggesting potential risks associated with price fluctuations.
Despite recent earnings beats, revenue has declined compared to the same quarter last year, raising questions about future growth sustainability.
The company has a relatively high price-to-earnings-growth ratio, which may indicate that the stock is overvalued compared to its growth rate.
Insider ownership is low at 2.60%, which may suggest a lack of confidence from company executives in the stock's future performance.

ILMN Forecast - Frequently Asked Questions

: According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Illumina is $127.21, with a high forecast of $200.00 and a low forecast of $80.00.
: 20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 2 sell ratings, 9 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
: According to analysts, Illumina's stock has a predicted upside of 34.39% based on their 12-month stock forecasts.
: Over the previous 90 days, Illumina's stock had 2 downgrades by analysts.
: Illumina has been rated by research analysts at Barclays, Canaccord Genuity Group, Citigroup, Evercore ISI, Guggenheim, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Robert W. Baird, Royal Bank Of Canada, Scotiabank, and Stephens in the past 90 days.
: Analysts like Illumina less than other "medical" companies. The consensus rating for Illumina is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ILMN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:ILMN) was last updated on 8/2/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Illumina (ILMN) Stock Forecast & Price Target